Background: Cellular angiofibroma is a rare benign tumor in the distal genitalia introduced by Nucci et al in 1997 that can occur in both women and men with an age range of 46 – 54 years. In women it usually occurs in the vulva and vagina. These tumors are often diagnosed as Bartholin cysts, vulvar cysts, myomas, and unspecified complex tumors. Objective: Report a case of cellular angiofibroma previously diagnosed with cervical myoma Case: A 51-year-old female patient para 5 abortion 0 with complaints of lumps that have been felt to come in and out since 4 months but since 1 week it feels enlarged and cannot be inserted again, and diagnosed as cervical tumor. History of menopause since 1 year ago. The general condition of the patient is good with vital signs within normal limits. On physical examination of the abdomen, there was no tumor mass, tenderness or flux. On inspection, there was a reddish mass coming out of the vaginal introitus with some blackish necrotic appearance. On vaginal examination, a mass with a solid consistency was found with the impression of the cervix with a border of the tumor stalk that was not palpable. In this patient, Total Abdominal Hysterectomy and Bilateral Salpingoophorectomy were performed and the tissue was examined for anatomical pathology with cervical angiofibroma results with non-specific chronic inflammation and atypical complex endometrial gland hyperplasia.  Conclusion : Cellular angiofibroma is a rare tumor that usually occur in the vulva and vagina, which is often diagnosed as Bartholin's cyst, vulvar cyst, myoma and unspecified complex tumor. Action in the form of total excision of tumor tissue gives a low recurrence. Keywords : Cervical angiofibroma, cervical tumor

No abstract

Tujuan: Mengetahui perbandingan respon terapi dan toksisitas regimen kemoterapi kombinasi Paclitaxel Carboplatin Ifosfamide dengan Paclitaxel Carboplatin pada kanker serviks stadium IIB. Metode: Sebanyak 30 pasien yang baru terdiagnosis kanker serviks stadium IIB dibagi menjadi dua kelompok terapi kombinasi yaitu kelompok Paclitaxel-Carboplatin-Ifosfamide (TIP) dan Paclitaxel-Carboplatin (TP). Volume tumor dan respon terapi diukur sebelum dan sesudah tiga siklus kemoterapi. Hasil:Tingkat penurunan rata-rata volume tumor pada kelompok Paclitaxel-Carboplatin-Ifosfamide dan Paclitaxel-Carboplatin sebesar (23,66% vs 39,08%). Tidak ada perbedaan secara bermakna angka respon parsial, angka respon progresif dan tidak ada respon antara kelompok dengan Paclitaxel-Carboplatin-Ifosfamide dengan kelompok Paclitaxel-Carboplatin dengan p > 0,05. Hasil antara Paclitaxel-Carboplatin-Ifosfamide dan Paclitaxel-Carboplatin pada respon parsial (46,7 % vs 73,3%), respon progresif (13,3% vs 13.3%), dan tidak ada respon (40,0 % vs 1,3%) dan toksisitas kelas 2 lebih dominan pada kelompok Paclitaxel-Carboplatin-Ifosfamide yaitu mual, kerontokan (53,3%) dan fatique, muntah (46,7%). Kesimpulan: Regimen kemoterapi kombinasi Paclitaxel-Carboplatin lebih efektif dalam menurunkan ukuran tumor kanker serviks stadium IIB dengan efek samping yang lebih minimal dibandingkan kombinasi Paclitaxel-Carboplatin-Ifosfamide. Comparison of Therapy Response and Toxicity of Combination Chemotherapy Regimens Between Paclitaxel, Carboplatin And Ifosfamide (PCI) with Paclitaxel and Carboplatin (PC) in Stadium IIB Cervical Cancer Abstract Objective: To compare the therapeutic response and toxicity of a combination chemotherapy regimen of Paclitaxel Carboplatin Ifosfamide with Paclitaxel Carboplatin in stage IIB cervical cancer. Methods: A total of 30 patients newly diagnosed with stage IIB cervical cancer were divided into two combination therapy groups, namely the Paclitaxel-Carboplatin-Ifosfamide (PCI) and Paclitaxel-Carboplatin (PC) groups. Tumor volume and clinical response were measured before and after three cycles. Result: The average reduction rate of tumor volume in the Paclitaxel-Carboplatin-Ifosfamide and Paclitaxel-Carboplatin groups was (23.66% vs 39.08%). There was no significant difference in the partial response rate, progressive response rate and no response between the Paclitaxel-Carboplatin-Ifosfamide group and the Paclitaxel-Carboplatin group with p > 0.05. Results between Paclitaxel-Carboplatin-Ifosfamide and Paclitaxel-Carboplatin on partial response (46.7% vs 73.3%), progressive response (13.3% vs 13.3%), and no response (40.0% vs 1, 3%) and class 2 toxicity was more dominant in the Paclitaxel-Carboplatin-Ifosfamide group namely nausea, hair loss (53.3%) and fatigue, vomiting (46.7%). Conclusion: The Paclitaxel-Carboplatin combination chemotherapy regimen is more effective in reducing the tumor size of stage IIB cervical cancer with lower side effects than the Paclitaxel-Carboplatin-Ifosfamide combination. Key words: cervical cancer, chemotherapy, side effects